Cargando…

Successful Long-Term Medical Management of Unresectable Insulinomas

In this paper, we present two patients with unresectable insulinomas and a literature review. Patient 1: A 58-year-old woman was diagnosed at age 42, with an insulinoma in the pancreatic tail and hepatic metastasis. She underwent distal pancreatectomy, splenectomy, hepatic wedge resection, and chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Spiro, Andrew J., Shakir, Mohamed K.M., Hoang, Thanh D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506377/
https://www.ncbi.nlm.nih.gov/pubmed/32999654
http://dx.doi.org/10.1159/000508996
_version_ 1783585004544065536
author Spiro, Andrew J.
Shakir, Mohamed K.M.
Hoang, Thanh D.
author_facet Spiro, Andrew J.
Shakir, Mohamed K.M.
Hoang, Thanh D.
author_sort Spiro, Andrew J.
collection PubMed
description In this paper, we present two patients with unresectable insulinomas and a literature review. Patient 1: A 58-year-old woman was diagnosed at age 42, with an insulinoma in the pancreatic tail and hepatic metastasis. She underwent distal pancreatectomy, splenectomy, hepatic wedge resection, and chemoembolization, with resolution of her symptoms. By age 48, her symptoms returned, with new hepatic metastasis. She started long-acting octreotide, with subsequent resolution of her symptoms. She has since had an unremarkable clinical course. Patient 2: A 48-year-old female was diagnosed at age 37. Numerous imaging modalities and two exploratory surgeries did not localize a mass. A distal pancreatectomy did not resolve her symptoms. She tried several medications before her symptoms were finally controlled with low-dose prednisone. She has continued prednisone and diazoxide treatment for the past decade, which controls her symptoms, along with diet modification. In conclusion, while prednisone is not standard therapy, it can control symptoms in patients with unresectable insu­linoma. Providers should be aware of available and emerging medical options. Patients with unresectable insulinomas will likely have better long-term survival rates than those quoted in historical literature. Additional studies are needed to elucidate survival rate and the long-term efficacy of medical therapies.
format Online
Article
Text
id pubmed-7506377
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-75063772020-09-29 Successful Long-Term Medical Management of Unresectable Insulinomas Spiro, Andrew J. Shakir, Mohamed K.M. Hoang, Thanh D. Case Rep Oncol Case Report In this paper, we present two patients with unresectable insulinomas and a literature review. Patient 1: A 58-year-old woman was diagnosed at age 42, with an insulinoma in the pancreatic tail and hepatic metastasis. She underwent distal pancreatectomy, splenectomy, hepatic wedge resection, and chemoembolization, with resolution of her symptoms. By age 48, her symptoms returned, with new hepatic metastasis. She started long-acting octreotide, with subsequent resolution of her symptoms. She has since had an unremarkable clinical course. Patient 2: A 48-year-old female was diagnosed at age 37. Numerous imaging modalities and two exploratory surgeries did not localize a mass. A distal pancreatectomy did not resolve her symptoms. She tried several medications before her symptoms were finally controlled with low-dose prednisone. She has continued prednisone and diazoxide treatment for the past decade, which controls her symptoms, along with diet modification. In conclusion, while prednisone is not standard therapy, it can control symptoms in patients with unresectable insu­linoma. Providers should be aware of available and emerging medical options. Patients with unresectable insulinomas will likely have better long-term survival rates than those quoted in historical literature. Additional studies are needed to elucidate survival rate and the long-term efficacy of medical therapies. S. Karger AG 2020-08-06 /pmc/articles/PMC7506377/ /pubmed/32999654 http://dx.doi.org/10.1159/000508996 Text en Copyright © 2020 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Spiro, Andrew J.
Shakir, Mohamed K.M.
Hoang, Thanh D.
Successful Long-Term Medical Management of Unresectable Insulinomas
title Successful Long-Term Medical Management of Unresectable Insulinomas
title_full Successful Long-Term Medical Management of Unresectable Insulinomas
title_fullStr Successful Long-Term Medical Management of Unresectable Insulinomas
title_full_unstemmed Successful Long-Term Medical Management of Unresectable Insulinomas
title_short Successful Long-Term Medical Management of Unresectable Insulinomas
title_sort successful long-term medical management of unresectable insulinomas
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506377/
https://www.ncbi.nlm.nih.gov/pubmed/32999654
http://dx.doi.org/10.1159/000508996
work_keys_str_mv AT spiroandrewj successfullongtermmedicalmanagementofunresectableinsulinomas
AT shakirmohamedkm successfullongtermmedicalmanagementofunresectableinsulinomas
AT hoangthanhd successfullongtermmedicalmanagementofunresectableinsulinomas